ATG-016

DRUG2 trials

Sponsors

Shanghai Antengene Corporation Limited

Conditions

Advanced Solid TumorsMyelodysplastic Syndrome

Phase 1

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

TerminatedNCT04691141

Shanghai Antengene Corporation LimitedMyelodysplastic Syndrome

Start: 2021-02-23End: 2023-09-19Updated: 2024-04-17

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors

TerminatedNCT05010525

Shanghai Antengene Corporation LimitedAdvanced Solid Tumors

Start: 2021-09-01End: 2022-11-14Updated: 2023-03-17